Mankind Pharma Results Earnings Call for Q3FY24
Conference Call with Mankind Pharma Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.02-02-2024
02-02-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023.01-02-2024
Mankind Pharma Q3 Net Profit Jumps 55% To Rs 460 Crore
Its revenue from operations rose to Rs 2,607 crore in the period under review from Rs 2,091 crore in the year-ago period, Mankind Pharma said in a statement.31-01-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Mankind Pharma Ltd.
Pharmaceuticals company Mankind Pharma announced Q3FY24 & 9MFY24 results: Q3FY24: Revenue from Operations at Rs 2,607 crore, 25% YoY growth Domestic revenue at Rs 2,400 crore, 20% YoY growth Export revenue at Rs 207 crore, 118% YoY growth EBITDA at Rs 611 crore, 39% YoY growth with a margin of 23.4% (up 240 bps YoY) PAT at Rs 460 crore, 55% YoY growth with a margin of 17.6% (up 350 bps YoY) Diluted EPS of Rs 11.3, 59% YoY growth (FV Re 1) 9MFY24: Revenue from Operations at Rs 7,894 crore, 18% YoY growth Domestic revenue at Rs 7,348 crore, 13% YoY growth Export revenue at Rs 546 crore, 154% YoY growth EBITDA at Rs 1,957 crore, 31% YoY growth with a margin of 24.8% (up 250 bps YoY) PAT at Rs 1,465 crore, 44% YoY growth with a margin of 18.6% (up 340 bps YoY) Diluted EPS of Rs 35.9, 44% YoY growth (FV Re 1) Cash flow from operations of Rs 1,636 crore, 23% YoY growth Net cash balance of Rs 2,756 crore as of 31st December 2023 Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said, “We are delighted to announce strong Q3 results with Domestic Growth of 20% YoY led by robust growth in Chronic, recovery in anti-infectives, and strong growth in modern trade and hospital sales. Our top 5 therapeutics by sales have outperformed the IPM by 1.5x. We have increased our market share in 18 out of the top 20 brands on both QoQ and YoY basis. These have resulted in a robust EBITDA growth of 39% YoY and PAT growth of 55% YoY in Q3. We continue to focus on improving cash flow from operations and optimising our working capital cycle.” Result PDF31-01-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Financial Results of Q3 FY2431-01-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on Financial Results for the quarter ended on December 31, 2023.31-01-2024
Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 31, 2024
Outcome of Board Meeting held today i.e. January 31, 202431-01-2024
Mankind Pharma Ltd - 543904 - Outcome Of Board Meeting Held Today I.E. January 31, 2024
Outcome of Board Meeting held today i.e. January 31, 202431-01-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor Conference Call for Q3 FY24 with Senior Management of Mankind Pharma Limited19-01-2024
Mankind Pharma Ltd - 543904 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company will be held on Wednesday, January 31, 2024, inter-alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended on December 31, 2023. Further, in continuation of our earlier letter dated December 27, 2023 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s ''Code of Conduct for Prevention of Insider Trading'', the trading window for trading in the securities of the Company shall remain closed till February 02, 2024. The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com.16-01-2024